Physician profile
David K Keith
NPI 1679551782
$7,144.89
in general payments reported to CMS, 2019-2025
41 companies · $561 in 2025
The $561 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $419 · 2021: $1,221 · 2022: $1,684 · 2023: $1,647 · 2024: $1,414 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.42 | 2021-2025 | |
| Novo Nordisk INC | $730.72 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $612.02 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $547.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $420.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.85 | 2019-2024 | Ofev, Jardiance |
| Amgen INC. | $278.85 | 2019-2025 | Otezla, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $243.05 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $230.47 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $207.49 | 2020-2024 | Eliquis, Camzyos |
| Xeris Pharmaceuticals, INC. | $187.42 | 2022-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $179.88 | 2020-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $156.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $139.05 | 2022 | |
| Amarin Pharma, INC. | $138.23 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.